Skip to main content
NIH funding notice PAR-18-690

Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional)

Closed on May 7, 2021.

Posted
March 1, 2018
Close date
May 7, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $162,334 in first-year total cost, median $81,167.

Most frequent study sections

  1. Therapeutic Approaches to Genetic Diseases Study Section[TAG]2

Most frequent institutions

  1. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
  2. UNIVERSITY OF COLORADO DENVER1
Competing awards under PAR-18-690 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021A novel treatment option for disorders of propionate metabolism1R03HD105916-01DEVITA, ROBERT JHOUTEN, SANDER MICHELICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY$84,584TAG
2020Population Health in Pediatric Sex Chromosome Aneuploidies1R03HD102773-01DAVIS, SHANLEEUNIVERSITY OF COLORADO DENVER, CO$77,750TAG

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-18-690: Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional) | ScienceDex | ConductScience